1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,346 | 1,352 | 11.11. | |
| 1,348 | 1,350 | 11.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.11. | SynAct Pharma Announces Attendance and Presentation at Upcoming Investor Conferences | 290 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 4, 2026 / SynAct Pharma (STO:SYNACT) - SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm:SYNACT), a clinical-stage biotechnology company focused on treating... ► Artikel lesen | |
| 03.11. | SynAct Pharma Announces Initiation of Coverage by BioVal BioStock Analytics | 289 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 3, 2026 / SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel... ► Artikel lesen | |
| 03.11. | SynAct Pharma Publishes Q3 2026 Interim Results | 201 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 3, 2026 / SynAct Pharma AB (publ) ("SynAct")(STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach... ► Artikel lesen | |
| 03.11. | SynAct Pharma AB Q3 Loss Narrows | 3 | RTTNews | ||
| SYNACT PHARMA Aktie jetzt für 0€ handeln | |||||
| 27.10. | SynAct Pharma Signs First Commercial Partnership for Resomelagon with Leading Brazilian Pharmaceutical Company | 418 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 27, 2026 / SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel... ► Artikel lesen | |
| 27.10. | SynAct Pharma AB: SynAct Pharma signs first commercial partnership for resomelagon with leading Brazilian pharmaceutical company | 228 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution"... ► Artikel lesen | |
| 22.09. | SynAct Pharma to Participate in Investor and Partnering Conferences | 437 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 22, 2026 / SynAct Pharma AB (publ) ("SynAct") (STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic... ► Artikel lesen | |
| 16.09. | SynAct Pharma: WHO Identifies Resomelagon as One Of Six Dengue Drug Candidates with Evidence Supporting Further Clinical Development | 435 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 16, 2026 / SynAct Pharma AB (publ) ("SynAct") (STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic... ► Artikel lesen | |
| 16.09. | SynAct Pharma AB: WHO identifies resomelagon as one of six dengue drug candidates with evidence supporting further clinical development | 407 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution"... ► Artikel lesen | |
| 07.09. | SynAct Pharma: Further Analysis of the Phase 2b ADVANCE Study Reinforces Phase 2b EXPAND Results and Supports Phase 3 Development - FDA Discussions on Trial Design Planned for Q4 2026 | 620 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 7, 2026 / SynAct Pharma AB (publ) ("SynAct")(STO:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach... ► Artikel lesen | |
| 03.09. | SynAct Pharma's CEO and CSO Sell Shares | 311 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 3, 2026 / SynAct Pharma AB (STO:SYNACT) ("SynAct Pharma" or the "Company") today announces that the Company's Chief Executive Officer, Jeppe Øvlesen, and the Company's... ► Artikel lesen | |
| 20.08. | SynAct Pharma AB: SynAct Pharma publishes Q2 2026 interim results | 248 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the second quarter 2026.
"With new capital secured and active partnering discussions underway, we are positionedto pursue the... ► Artikel lesen | |
| 19.08. | SynAct Pharma AB: SynAct Pharma progresses first commercial agreement on resomelagon for treatment of dengue in Brazil - term sheet signed | 366 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announces that the company has signed... ► Artikel lesen | |
| 05.08. | SynAct Pharma AB: SynAct Pharma receives favorable US patent decision for immediate-release resomelagon tablet formulation | 631 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today announced that the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) has issued a favorable Decision on Appeal in... ► Artikel lesen | |
| 20.07. | SynAct Pharma AB: SynAct Pharma strengthens financial position and strategic flexibility to advance partnering discussions and Phase III readiness | 928 | GlobeNewswire (Europe) | SynAct Pharma AB ("SynAct" or the "Company") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company developing resolution therapies for inflammatory diseases, today announced that it has... ► Artikel lesen | |
| 29.06. | SynAct Pharma AB: BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study | 870 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through resolution therapy, today provides an update following... ► Artikel lesen | |
| 15.06. | SynAct Pharma AB: Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, regulatory interactions, and partnering | 573 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, reported today that resomelagon in combination... ► Artikel lesen | |
| 12.06. | SynAct Pharma AB: SynAct obtains key US patent for resomelagon securing exclusivity until 2044 | 709 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") announced today that the United States Patent and Trademark Office (USPTO) have provided the issue notification of US patent 12,661,336 with issue date 23 June 2026... ► Artikel lesen | |
| 11.06. | SynAct Pharma AB: Report from the 2026 Annual General Meeting of SynAct Pharma AB (publ) | 528 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) held its Annual General Meeting today, Thursday 11 June 2026, at the offices of MAQS Advokatbyrå in Stockholm. Attorney Eric Ehrencrona from MAQS Advokatbyrå was elected as chairman... ► Artikel lesen | |
| 27.05. | SynAct Pharma AB: SynAct Pharma publishes Q1 2026 interim results | 442 | GlobeNewswire (Europe) | SynAct Pharma AB (publ) ("SynAct") today publishes the interim report for the first quarter 2026.
"As we close the first quarter of 2026, SynAct Pharma is in a stronger position than at any previous... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 56,52 | -0,98 % | Machtwechsel in den USA! Warum Bayer boomt, TeamViewer massiv einbricht und Almonty Industries vor einer massiven Rally stehen könnte! | Machtwechsel in Washington: Die Demokraten haben bei den US-Zwischenwahlen den Senat zurückerobert und wohl auch das Repräsentantenhaus. Für Donald Trump bedeutet das geteilte Macht für den Rest seiner... ► Artikel lesen | |
| ABBVIE | 262,20 | -0,42 % | Eli Lilly kauft AtaiBeckley für 2,8 Milliarden Dollar - wer behandelt künftig die Patienten? | ||
| ELI LILLY | 1.281,60 | -0,17 % | Baron Funds Sees Eli Lilly's (LLY) Mounjaro, Zepbound and Orforglipron as Transformational | ||
| MERCK & CO | 131,86 | -0,57 % | Merck & Co. (MRK): US-Pharmagigant bereitet die nächste Rally vor! | Befreiungsschlag an der Widerstandslinie? Rückblick Im Chart sehen wir nach einer Seitwärtsphase einen steilen Anstieg bis August. Darauf folgte eine Konsolidierung. Die Bullen lauern nun knapp unterhalb... ► Artikel lesen | |
| BRISTOL-MYERS SQUIBB | 55,71 | -0,98 % | Beste DAX-Aktie des Jahres!: Bayer: Ist die US-Zulassung für Asundexian der nächste Kurstreiber | © Foto: Hendrik Schmidt - dpa-ZentralbildEin günstiger Beipackzettel und ein Preis im Rahmen der Erwartungen: Die Bank of America sieht im neuen Bayer-Medikament Asundexian deutlich mehr Potenzial,... ► Artikel lesen | |
| INNOCAN PHARMA | 1,045 | -1,42 % | Innocan Pharma: Erste Tranche zu - was jetzt wichtig wird | ||
| DOCMORRIS | 20,480 | +0,29 % | Ihre wichtigsten Termine: Heute im Blickpunkt: Moderna, DocMorris, Applied Materials, Siemens und Cisco | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: DE0008404005... ► Artikel lesen | |
| INCYTE | 108,30 | +0,98 % | Incyte präsentiert auf der ASH 2026 neue Daten, die die Fortschritte im gesamten hämatologischen Portfolio verdeutlichen | Zu den neuen Daten zu myeloproliferativen Neoplasien (MPN) gehören INCA033989, Incytes "First-in-Class"-monoklonaler Antikörper, der auf mutiertes Calreticulin (mutCALR) abzielt, bei der Erstlinienbehandlung... ► Artikel lesen | |
| SINOPHARM | 1,904 | -2,01 % | SINOPHARM (01099): ANNOUNCEMENT (1) CONTINUING CONNECTED TRANSACTIONS: 2026 PROCUREMENT FRAMEWORK AGREEMENT, 2026 SALES FRAMEWORK AGREEMENT, 2026 EPC ... | ||
| HAPPY BELLY FOOD GROUP | 0,935 | +0,54 % | Happy Belly Food Group Inc.: Happy Belly Food Group's Heal Wellness QSR Secures Real Estate Location for Multi-Unit Franchisee in Montreal's Mile End | Toronto, Ontario--(Newsfile Corp. - November 12, 2026) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leading consolidator of emerging restaurant brands... ► Artikel lesen | |
| COMPASS PATHWAYS | 8,350 | +0,60 % | Compass Pathfinder Limited: Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th | Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Jefferies... ► Artikel lesen | |
| HIGH TIDE | 2,290 | -0,43 % | High Tide erwirbt etablierten Cannabis-Laden in Chestermere, Alberta | CALGARY, AB / 9. Oktober 2026 / IRW-Press / High Tide Inc. ("High Tide" oder das "Unternehmen") (Nasdaq: HITI) (TSXV: HITI) (FWB: 2LYA), das erfolgreiche, auf
den Einzelhandel fokussierte Unternehmen... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 284,00 | +0,71 % | Ligand Pharmaceuticals: Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million | JUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc.... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 220,20 | +0,14 % | Piper Sandler raises Jazz Pharmaceuticals price target on Ziihera outlook | ||
| SELLAS LIFE SCIENCES | 7,480 | -0,27 % | Sellas Life Sciences Group: Regal-Studie erreicht die nächste Marke, aber die Aktie fällt - vor der Schlussanalyse |
SYNACT PHARMA AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -2,45 % bei einem Aktienkurs von 1,354 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNACT PHARMA AB finden Sie auf Wallstreet Online.